Bristol Myers Squibb Gets CHMP Opinion for Breyanzi in Lymphoma
Recommendation based on the Phase 2 TRANSCEND FL study in which 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving complete response Across clinical...
Category : Clinical Research, Pharma & Healthcare Financing
Immunome Closes Upsized Offering, Underwriters Exercise Option
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public...
Inhalon Biopharma’s Inhaled RSV Antibody to Enter Trials
New at-home RSV treatment represents a potential breakthrough in addressing the burden of respiratory diseases, especially in vulnerable pediatric and elderly populations nhalon Biopharma, Inc. (Inhalon),...
KORU Medical Announces Phase III Trial for New Nephrology Drug
KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and...
Vertex Announces CASGEVY® Reimbursement for SCD in England
– Agreement means eligible sickle cell disease (SCD) patients in England now have access to CASGEVY – – Agreement for CASGEVY in transfusion-dependent beta thalassemia...
Meiji Seika Pharma Gets Approval for Domestic KOSTAIVE® Production
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment...
Nomi Health named ACAP preferred vendor to boost health equity
Nomi Health Joins the Association for Community Affiliated Plans to Support Not-for-Profit Safety Net Health Plans Nomi Health, a leading direct healthcare company, today announced...
Owkin doses first patient in AI-optimized trial of OKN4395.
Owkin, the first end-to-end AI-biotech that uses agentic AI to revolutionize drug discovery, development, and diagnostics, today announced that the first patient has been dosed...
Merck, Eisai Update Phase 3 LEAP-015 Trial for GE Adenocarcinoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LEAP-015 trial evaluating...
Innate Pharma Doses First Patient in Phase 1 Study of IPH4502
IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4 Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)...
Corstasis Announces FDA Acceptance for Bumetanide Nasal Spray
PDUFA Target Action Date Set for September 14, 2025 Corstasis Therapeutics Inc. (www.corstasis.com), a clinical-stage MedTech pharmaceutical company developing innovative, practical therapies for fluid overload,...
Systech Unveils Semi-Automated Aggregation Solution for Pharma
Systech, part of Markem-Imaje and Dover and a leading provider of digital identification and traceability software solutions, today announced the introduction of the ST16 Semi-Automated Multi-Aggregation Station for pharmaceutical...
Datar Cancer Genetics Launches Tumor-Agnostic MRD Blood Test
The Target-MRD blood test uses a combination of tumor-informed and tumor-agnostic molecular features for personalized, accurate and more effective monitoring of molecular residual disease. Datar...
Breakthrough Study Shows MatriDerm® Superior in Wound Healing
MatriDerm® by MedSkin Solutions Dr. Suwelack AG Proven to Enhance Cell Activity, Reduce Inflammation, and Deliver Better Wound Healing Outcomes in Research Study MedSkin Solutions...